Cellular therapies for rheumatic disease

Cellular therapies, particularly chimeric antigen receptor (CAR)-modified lymphocytes, have progressed from experimental oncology into serious consideration for selected autoimmune rheumatic diseases. Autologous and emerging allogeneic CAR-T platforms now offer the possibility of deep, drug-free remission in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), and related conditions for which conventional therapies remain inadequate. This timely article reviews the rationale, current clinical experience, safety profile, and future directions of cell therapies in rheumatology with a focus on efficacy, safety, and "immune reset" in autoimmune rheumatic disease. The review is particularly pertinent as multiple parallel cell-based platforms (autologous and allogeneic CAR T cells, transient RNA CARs, CAR-NK, and T cell engagers) are entering the rheumatology space faster than practice guidelines or trial frameworks can fully adjust.

Recent studies show that CD19-directed CAR T cells can induce deep B-cell depletion with high rates of drug-free remission in refractory SLE and promising responses in SSc and IIM, accompanied by distinctive toxicity patterns such as mostly low-grade CRS, rare ICANS, and the newly described organ-specific LICATS. Parallel work demonstrates mechanistic "immune reset" (including type I IFN pathway suppression and naïve-skewed B-cell repopulation), expansion of indications to neurologic autoimmunity, emergence of off-the-shelf platforms (allogeneic CARs, γδ-CAR, CAR-NK, RNA CARs), and early human experience with CD19- and BCMA-directed T cell engagers in rheumatic disease.

Collectively, these findings position cellular therapies as powerful, potentially transformative options for highly selected patients with severe, refractory lupus and autoimmune rheumatic disease, but also underscore the need for disciplined trial design, long-term safety surveillance, and strategies to ensure equitable access.